(firstQuint)Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients.

 The objective of this study was to evaluate the episode duration of a herpes labialis recurrence, following a 5-day treatment with 5-time daily topical administration of ME-609 or acyclovir cream, in immunocompromised adults, 18 years and older.

 This interim report summarizes the results for short-term observations, i.

e.

, during the initial study recurrence.

 A final study report will be prepared when the long-term follow-up is completed.

.

 Study of ME-609 and Acyclovir for Treatment of Herpes Simplex Labialis in Immunocompromised Patients@highlight

The purpose of this study is to evaluate the episode duration of a herpes labialis recurrence in immunocompromised patients treated with ME-609 or Acyclovir.

